Angiopoietin-2 associates with poor prognosis in Moyamoya angiopathy.

Gemma GorlaAntonella PotenzaTatiana CarrozziniGiuliana PollaciFrancesco AcerbiIgnazio G VetranoPaolo FerroliIsabella CanaveroNicola RifinoAnna BersanoLaura Gatti

Published in: Annals of clinical and translational neurology (2024)

Our results pointed out Ang-2 as a reliable biomarker mirroring arterial steno-occlusion and vascular instability of MA in CSF and blood, providing a candidate factor for patient stratification. This pilot study may pave the way to the validation of a biomarker to identify progressive MA patients deserving a specific treatment path.

Keyphrases

poor prognosis
long non coding rna
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
multiple sclerosis
angiotensin ii
case report
patient reported outcomes
middle cerebral artery
patient reported
combination therapy